On the other hands, the remaining 6 patients who needed a treatment interruption due to AST and/or ALT elevation with a CTCAE grade ≥2 discontinued nintedanib treatment without resumption because of patient rejection or acute hypochondriac pain (2 patients each) and a deterioration in their physical condition or eosinophilia (1 patient each). The gene discussed is GPT; the disease is Increased total eosinophil count.